These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 9576051)

  • 1. Antiretroviral therapies.
    Owen WF
    Clin Podiatr Med Surg; 1998 Apr; 15(2):227-39. PubMed ID: 9576051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standard treatments for HIV, Spring 1997.
    Smith D
    AIDS Treat News; 1997 Apr; (No 269):4-5. PubMed ID: 11364255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. State of the art: antiretroviral and prophylactic treatments in HIV/AIDS.
    Porche DJ
    Nurs Clin North Am; 1999 Mar; 34(1):95-112. PubMed ID: 9922281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonnucleoside reverse transcriptase inhibitors.
    Murphy RL
    AIDS Clin Care; 1997 Oct; 9(10):75-7, 79. PubMed ID: 11364757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 protease inhibitors.
    Eron JJ
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S160-70. PubMed ID: 10860901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical issues regarding the use of antiretroviral therapy for HIV infection.
    Deeks SG
    West J Med; 1998 Feb; 168(2):133-9. PubMed ID: 9499754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New antiretrovirals and new combinations.
    Havlir DV; Lange JM
    AIDS; 1998; 12 Suppl A():S165-74. PubMed ID: 9632999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection.
    Gerber JG
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S123-9. PubMed ID: 10860896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus-infected patients: protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors.
    Tavel JA; Miller KD; Masur H
    Clin Infect Dis; 1999 Mar; 28(3):643-76. PubMed ID: 10194094
    [No Abstract]   [Full Text] [Related]  

  • 11. Antiretroviral agents: the next generation.
    Deeks SG
    AIDS Clin Care; 1998 May; 10(5):33-6, 39-40. PubMed ID: 11365427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
    Joly V; Yeni P
    Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV therapeutics: past, present, and future.
    Abu-ata O; Slim J; Perez G; Smith SM
    Adv Pharmacol; 2000; 49():1-40. PubMed ID: 11013759
    [No Abstract]   [Full Text] [Related]  

  • 14. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing issues related to antiretroviral therapy.
    Lesho EP; Gey DC
    Am Fam Physician; 2003 Aug; 68(4):675-86. PubMed ID: 12952384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors.
    Introcaso CE; Hines JM; Kovarik CL
    J Am Acad Dermatol; 2010 Oct; 63(4):549-61; quiz 561-2. PubMed ID: 20846563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and experience with reverse transcriptase inhibitors and protease inhibitors.
    Vella S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S58-61. PubMed ID: 8595511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [AIDS; new developments. II. Treatment of HIV infection].
    Borleffs JC; Esseveld F; Hoepelman IM; Boucher CA
    Ned Tijdschr Geneeskd; 1997 May; 141(21):1036-43. PubMed ID: 9340560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV treatment options.
    Smith D
    AIDS Treat News; 1998 May; (No 294):4-5. PubMed ID: 11365404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.